Opicapone: a short lived and very long acting novel catechol‐<scp>O</scp>‐methyltransferase inhibitor following multiple dose administration in healthy subjects

Abstract

Despite its short elimination half-life, opicapone markedly and sustainably inhibited erythrocyte S-COMT activity making it suitable for a once daily regimen.